Aspirin and Preeclampsia
Research type
Research Study
Full title
Investigating the role of neutrophils in aspirin treatment for women at high risk of preeclampsia
IRAS ID
294761
Contact name
Suchita Nadkarni
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The exact mechanisms by which aspirin prevents the development of preeclampsia in high-risk women are currently not fully known. Furthermore, a small proportion of high-risk women who are on low-dose aspirin (LDA) still go on to develop preeclampsia.
This longitudinal observational study will assess the immune profile in women who are taking low dose aspirin (LDA) in pregnancy. As part of routine care, women at high risk of developing preeclampsia are treated with LDA from 16 weeks gestation.
The study will be conducted at Barts Health NHS Trust. The study population will comprise of 2 groups of participants:
1. Those who respond to LDA and do not develop preeclampsia (responders)
2. Participants who do not respond to LDA and develop preeclampsia (non responders)Participants will be consented at their booking appointment. Women will be eligible if they have a singleton pregnancy and are aged over 18 years. They will have an additional blood sample taken at 12, 20, 28 and 36 weeks gestation. The blood samples will be tested to assess immune cell function, metabolism and genetics. This will identify cumulative changes in immunobiology at key time points in pregnancy.
REC name
London - Harrow Research Ethics Committee
REC reference
21/PR/1127
Date of REC Opinion
7 Oct 2021
REC opinion
Further Information Favourable Opinion